Astbury Conversation

Main Sponsors

MedImmune

MedImmune pioneers innovative research across key therapeutic areas including RIA, cardiovascular & metabolic disease, oncology, neuroscience, and more. We develop medicines for unmet medical needs worldwide. We’re an industry leader in personalized medicine – developing new products that may allow doctors to prescribe a specific, customized treatment for each patient’s individual needs. We are the global biologics research and development arm of our parent company AstraZeneca, a recognized global leader in biopharmaceutical research and development. By combining AstraZeneca’s worldwide presence with our distinct and unique culture, processes, and standards, we continue to solve global healthcare challenges, redefine science, deliver better medicines, and help people live longer, healthier lives.

UCB

UCB aspires to be the patient-centric global biopharma leader, making a difference to the lives of people living with severe diseases. UCB is a global biopharmaceutical company, with a focus on neurology and immunology. Looking ahead, we have a solid platform for continuous growth through 2022 with our core products Cimzia®, Vimpat® and Neupro® and Keppra®, and we are preparing the launches of our next wave of potential medicines to help patients with epilepsy, lupus and osteoporosis. At the same time, we are very excited about the progress in our early pipeline. The key element of our evolution is to focus on the delivery of increased patient value. There is no such thing as an “average patient”. We want to use all the tools, channels and scientific advances at our disposal to develop a better understanding of the various expressions of a disease and embed the real needs of specific patient populations in our science and innovation process. Rather than starting researching any new drug with the science alone, we want to better connect patients with science and science with patients. Better understanding the reality of patients living with neurological and immunological disorders will enable us to take a more holistic approach to care, ensuring that ultimately the right drug and the right care reaches the right patients in order for them to live the lives they choose.

Sponsors

Advion is a leader in mass spec solutions for chemical biology. Featuring fast reaction monitoring ionization sources including ESI and APCI, all in a compact, single quad package.

Astex is a leader in innovative drug discovery and development, committed to the fight against cancer and diseases of the central nervous system. We are a leader in innovative small-molecule therapeutics with particular expertise in fragment-based drug discovery, the most important advance in discovery chemistry in the last 20 years. Although our discovery platform has been successfully applied to therapeutic targets addressing a variety of disease areas, our primary clinical area of focus is currently cancer.  In addition, we are expanding our capabilities and building expertise in the area of fragment-based drug discovery diseases of the CNS. For more information about Astex Pharmaceuticals, please visit http://www.astx.com. For more information about our parent company,  Otsuka Pharmaceutical, please visit http://www.otsuka.com/en/

A global pharmaceutical company with a major UK presence. Our purpose is to push the boundaries of science to deliver life-changing medicines. The best way we can help patients is to be science-led and share this passion with the scientific, healthcare and business communities of the UK.

The British Biophysical Society encourages and disseminates advances in the application of physics and physical chemistry to biological systems.

Exploring the molecular mechanisms that underpin key biological processes, the Biochemical Journal is a leading bioscience journal publishing high-impact scientific research papers and reviews on the latest advances and new mechanistic concepts in the fields of biochemistry, cellular biosciences and molecular biology.

Biolin Scientific is a leading Nordic instrumentation company with roots in Sweden and Finland. Our customers include companies working with life science, energy, chemicals, and advanced materials development, as well as academic and governmental research institutes. Our precision instruments help develop better solutions for energy and materials, and perform research at the frontiers of science and technology.

BMC Biology is the flagship biology journal of the BMC series, publishing peer-reviewed research and methodology articles of special importance and broad interest in any area of biology, as well as commissioned reviews, opinion pieces, comment and Q&As on topics of special or topical interest.

Since Bio-Rad was founded over six decades ago, we have continued to provide the healthcare industry with innovative and useful products that help life science researchers accelerate the discovery process and medical diagnostic labs obtain faster, better results. Throughout our existence, we have built long-lasting customer relationships that help advance our research and development efforts in the introduction of new products and solutions. Today, Bio-Rad is a global leader, with a team of over 8,250 employees and a global network of operations that serves our life science research and clinical diagnostics customers, helping people live longer, healthier lives.

Bruker enables scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, productivity and customer success in life science molecular research, in applied and pharma applications, and in microscopy, nano-analysis and industrial applications. In recent years, Bruker has also become a provider of high-performance systems for cell biology, preclinical imaging, clinical phenomics and proteomics research, clinical microbiology, and for molecular pathology research.

CellLogo_WhiteBackground

Cell Press is a leading publisher of cutting-edge biomedical research and reviews. We drive science forward and promote cross-pollination of ideas with our passion for excellence and commitment to innovation. Our aim is to engage the scientific community by communicating important, exciting discoveries made today that will impact the future of research.

Dell empowers countries, communities, customers and people everywhere to use technology to realize their dreams. Customers trust us to deliver technology solutions that help them do and achieve more, whether they’re at home, work, school or anywhere in their world. Learn more about our story, purpose and people behind our customer-centric approach.

Developing protein analysis tools that transform our understanding of how the biological world operates in real time.

GE Healthcare Life Sciences is a world-class provider of advanced technologies for life science research and biopharmaceutical manufacturing. Providing tools for drug discovery, biopharmaceutical manufacturing and cellular technologies, enabling research scientists and specialists around the world to be more productive, effective and creative with regards to their research. It is our vision is to be the start-to-finish bioprocessing solution provider, the partner of choice in cells and protein research and the leader in life sciences services. Our broad expertise in life sciences drives our commitment to help researchers understand life at a molecular level and develop innovations to prevent, diagnose, treat and cure disease. Our goal is to deliver research outcomes that help our customers to provide better care to more people around the world, at a lower cost and in a sustainable way.

Heptares is a clinical-stage company creating novel medicines targeting G protein-coupled receptors (GPCRs), a superfamily of receptors linked to a wide range of human diseases. Our proprietary StaR® technology and structure-based drug design (SBDD) capabilities are enabling us to build an exciting pipeline of new medicines with potential to transform the treatment of Alzheimer’s disease, schizophrenia, cancer, migraine, metabolic disease, and other indications. Our ability to address highly validated, yet historically undruggable, GPCRs has also attracted multiple pipeline and technology partners including Allergan, AstraZeneca, Daiichi Sankyo, Kymab, Morphosys, PeptiDream, Pfizer and Teva.

The International Journal of Molecular Sciences is an open access journal providing an advanced forum for biochemistry, molecular and cell biology, and molecular biophysics, and is published monthly online by MDPI with an average APT (article publishing time from submission to publication) of 37 days.

IJMS is covered by leading indexing services, including PubMed (Medline), the Science Citation Index Expanded (Web of Science) and Scopus. The most recent Impact Factor (IF) for the year 2016 is 3.226.

Astbury Conversation participants could enjoy 10% discount if they would like to publish a full paper in IJMS. Please contact Rayna Ren (rayna.ren@mdpi.com) or Celia Xu (celia.xu@mdpi.com) for more information.

The Journal of Biological Chemistry welcomes high-quality science that seeks to elucidate the molecular and cellular basis of biological processes. Papers published in JBC can therefore fall under the umbrellas of not only biological chemistry, chemical biology, or biochemistry, but also allied disciplines such as biophysics, systems biology, RNA biology, immunology, microbiology, neurobiology, epigenetics, computational biology, ’omics, and many more. The outcome of our focus on papers that contribute novel and important mechanistic insights, rather than on a particular topic area, is that JBC is truly a melting pot for scientists across disciplines. In addition, JBC welcomes papers that describe methods that will help scientists push their biochemical inquiries forward and resources that will be of use to the research community.

JPK Instruments AG is a world-leading manufacturer of nanoanalytic instruments - particularly atomic force microscope (AFM) systems and optical tweezers - for a broad range of applications reaching from soft-matter physics to nano-optics, from surface chemistry to molecular biology and from cell biology to biomedicine. From its earliest days applying atomic force microscope (AFM) technology, JPK has recognized the opportunities provided by nanotechnology for transforming life sciences and soft matter research.

Molecular Systems Design & Engineering provides a hub for cutting-edge research into how understanding of molecular properties, behaviour and interactions can be used to design and assemble better materials, systems, and processes to achieve specific functions. These may have applications of technological significance and help address global challenges.

Crossing the boundary between chemistry and chemical engineering, this unique new journal is a joint venture between the Royal Society of Chemistry and the Institution of Chemical Engineers (IChemE).

Nature Communications is an open access journal that publishes high-quality research from all areas of the natural sciences. Papers published by the journal represent important advances of significance to specialists within each field.

Founded in the mid-1970s as a collective of scientists committed to developing innovative products for the life sciences industry, New England Biolabs is now a recognized world leader in the discovery, development and commercialization of recombinant and native enzymes for genomic research.

Portland Press Limited is a leading provider of high-quality publishing and knowledge dissemination solutions. We make it easier for small and large organizations to manage their business.

Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $20 billion and approximately 65,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services.

VWR has long been the leading global, independent provider of product and service solutions to laboratory and production customers, enabling science for customers in the pharmaceutical, biotechnology, industrial, education, government and healthcare industries.